SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT. A live webcast of the call will be available on the ...

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT. A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. A re ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supplyAnaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) and AnaptysBio, Inc. (An ...

One stock that might be an intriguing choice for investors right now is AnaptysBio, Inc. (ANAB) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking plac ...

Company Presentation - AnaptysBio Inc's president and CEO Daniel Faga will present at the 43rd Annual J P Morgan Healthcare Conference on January 14 2025 at 4 30pm PT 7 30pm ET [1] - A live webcast of the presentation will be available on the investor section of the Anaptys website with a replay available for at least 30 days following the event [2] Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [3] - The company's lead program rosnilimab is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis [3] - AnaptysBio's portfolio includes ANB033 in Phase 1 trials and ANB101 soon to enter clinical development [3] - The company has licensed multiple therapeutic antibodies to GSK including an anti-PD-1 antagonist and an anti-TIM-3 antagonist [3] Contact Information - Nick Montemarano Senior Director of Investor Relations and Strategic Communications can be reached at 858 732 0178 or investors@anaptysbio com [4]

Core Viewpoint - AnaptysBio, Inc. (ANAB) experienced a significant decline in share price by 32.8% following the announcement of unsuccessful results from its phase IIb study of ANB032, a BTLA agonist, leading to the discontinuation of further investment in this asset [1][2][9]. Company Performance - AnaptysBio's stock has decreased by 27.6% year-to-date, contrasting with an industry decline of 8.1% [3]. Study Details - The ARISE-AD study assessed the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 in patients with moderate-to-severe atopic dermatitis, enrolling 201 patients with a mean baseline EASI score of 27.3 [4][5]. - Patients were randomized to receive different dosages of ANB032 or placebo over 12 weeks, but the drug did not meet the primary endpoint of achieving at least a 75% improvement in EASI score [6]. - None of the secondary endpoints were met, including EASI-90 and itch severity reduction, with higher placebo response rates observed particularly in the U.S. [7]. Safety Profile - Despite the disappointing efficacy results, ANB032 was well tolerated across all doses, with no safety signals reported [8]. Future Focus - AnaptysBio plans to shift focus to other candidates, including rosnilimab for rheumatoid arthritis and ANB033 and ANB101 in clinical development [10][11]. - The company anticipates a cash balance of approximately $415 million by the end of 2024, extending its cash runway guidance through the end of 2027 [12].

Core Insights - AnaptysBio, Inc. announced that investigational ANB032 did not meet primary and secondary endpoints in the ARISE-AD trial for moderate-to-severe atopic dermatitis [1][4] - The company will discontinue further investment in ANB032 and focus on its autoimmune portfolio [2] - ANB032 was well tolerated with no safety signals observed across all doses [6] Study Details - The ARISE-AD trial enrolled 201 patients with a mean baseline EASI score of 27.3, including both biologics naïve and experienced patients [2] - Patients were randomized to receive different dosing regimens of ANB032 or placebo for 12 weeks [3] - The primary endpoint was not met, with no significant improvement in EASI-75 or other secondary endpoints at Week 14 [4] Efficacy Observations - Absolute response rates approached the minimum target product profile, but higher placebo response rates were noted, particularly in the U.S. [5] - Despite the lack of efficacy, ANB032 was reported to be safe and well tolerated [6] Market Reaction - Following the announcement, AnaptysBio's stock price fell by 36.3%, trading at $14.72 [7]

Core Insights - AnaptysBio, Inc. announced that its investigational drug ANB032 did not meet primary and secondary endpoints in the ARISE-AD trial for moderate-to-severe atopic dermatitis, leading to the decision to discontinue further investment in this asset [1][2][3] - The company plans to focus resources on its autoimmune portfolio, particularly on rosnilimab, which targets PD-1+ T cells, with upcoming data releases anticipated in early 2025 and 2026 [2][7] - AnaptysBio reported a year-end 2024 cash balance of approximately $415 million, extending its cash runway guidance through the end of 2027, excluding potential milestones and royalties from GSK [1][2] Study Details - The ARISE-AD study involved 201 patients with a mean baseline EASI score of 27.3, randomized to receive different doses of ANB032 or placebo over 12 weeks [2][3] - ANB032 was well tolerated across all doses, with no safety signals observed, although it did not achieve the primary endpoint of EASI-75 improvement [3][5] - The study noted higher placebo response rates than historical norms, particularly in the U.S., despite some durable off-drug responses observed in patients treated with ANB032 [4][5] Future Developments - AnaptysBio anticipates sharing top-line Phase 2b data for rosnilimab in rheumatoid arthritis in February 2025, followed by Phase 2 data for ulcerative colitis in Q1 2026 [2][7] - The company is also advancing other programs, including ANB033 and ANB101, with ANB033 currently in Phase 1 trials [7]

Company Overview - AnaptysBio, Inc. (ANAB) is part of the Medical group, which consists of 1022 companies and ranks 3 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Analysis - Year-to-date, AnaptysBio, Inc. has returned approximately 4%, outperforming the Medical sector's average return of 0.5% [4] - Over the past three months, the Zacks Consensus Estimate for ANAB's full-year earnings has increased by 11.9%, reflecting improved analyst sentiment [4] Industry Context - AnaptysBio, Inc. operates within the Medical - Biomedical and Genetics industry, which includes 504 stocks and currently ranks 65 in the Zacks Industry Rank [6] - Stocks in this industry have experienced an average loss of about 7% year-to-date, indicating that ANAB is performing better than its peers in this specific sector [6] Comparative Analysis - Another notable stock in the Medical sector, Castle Biosciences, Inc. (CSTL), has achieved a year-to-date return of 38.1% and has a Zacks Rank of 1 (Strong Buy) [5] - Both AnaptysBio, Inc. and Castle Biosciences, Inc. are expected to continue their solid performance in the Medical sector [7]

Core Viewpoint - AnaptysBio, Inc. (ANAB) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to stock price fluctuations based on their buying or selling activities [4]. Business Outlook - The upgrade in Zacks Rank for AnaptysBio indicates an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5][10]. - Over the past three months, the Zacks Consensus Estimate for AnaptysBio has increased by 3.4%, reflecting analysts' growing confidence in the company's earnings potential [8]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - AnaptysBio's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].